Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

clinical trial

  • Home
  •  
  • clinical trial



  • Most Read
  • Latest Comments
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • Can a sleep disorder signal depression? Medibio study says yes
    Can a sleep disorder signal depression? Medibio study says yes
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    Why one contentious FDA drug approval is good news for Actinogen Medical

    Whether you’re running for the train, or running from a lion, cortisol- the stress hormone, plays an important role in making sure you aren’t late, or eaten.  Except, too much cortisol has detrimental effects to the brain and our health, with research suggesting that cortisol dysregulation can affect cognitive function and harm brain cells in

    Read More
    Public
  • Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark
    • News

    Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark

    Since the commencement of their program to fight grain storage pests, Agriculture technology company Bio-Gene Technology (ASX: BGT) continues to report strong trial results with current trials reaching the six-month mark and still effectively preventing pest growth.  As the world population continues expanding and higher food storage levels are required, loss of grains and grain-based

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.